I have had the stock in Isotechnika since 2000 when it was about $4 and faithfully held on all these years expecting a breakout to always be forthcoming.  There have been many years of disappointment. The one lesson learned is that a good scientist does not make for a good business manager. I am hopeful 2008 will be the turnaround year. I expect the following events to occur in 2008.  The appointment of a new CEO with good business management skills, a new contract signed for the distribution of ISA247 for psoriasis, the receipt of milestone payments of $75M and $35M along with the completion of phase 3 trials for psoriasis.